DK0667354T3 - Cytotoksisk faktor forbundet med dissemineret sklerose, dens detektion og kvantificering - Google Patents

Cytotoksisk faktor forbundet med dissemineret sklerose, dens detektion og kvantificering

Info

Publication number
DK0667354T3
DK0667354T3 DK95420031T DK95420031T DK0667354T3 DK 0667354 T3 DK0667354 T3 DK 0667354T3 DK 95420031 T DK95420031 T DK 95420031T DK 95420031 T DK95420031 T DK 95420031T DK 0667354 T3 DK0667354 T3 DK 0667354T3
Authority
DK
Denmark
Prior art keywords
quantification
detection
factor associated
cytotoxic factor
disseminated sclerosis
Prior art date
Application number
DK95420031T
Other languages
English (en)
Inventor
Herve Perron
Francois Rieger
Bernard Mandrand
Tomas Dobransky
Original Assignee
Bio Merieux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Merieux filed Critical Bio Merieux
Application granted granted Critical
Publication of DK0667354T3 publication Critical patent/DK0667354T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/16—Dendrimers and dendritic polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/964—Chemistry: molecular biology and microbiology including enzyme-ligand conjugate production, e.g. reducing rate of nonproductive linkage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/827—Lectins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/828—Protein A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK95420031T 1994-02-15 1995-02-15 Cytotoksisk faktor forbundet med dissemineret sklerose, dens detektion og kvantificering DK0667354T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9401946A FR2716198B1 (fr) 1994-02-15 1994-02-15 Facteur cytotoxique tel qu'associé à la sclérose en plaques, sa détection et sa quantification.

Publications (1)

Publication Number Publication Date
DK0667354T3 true DK0667354T3 (da) 2002-01-14

Family

ID=9460272

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95420031T DK0667354T3 (da) 1994-02-15 1995-02-15 Cytotoksisk faktor forbundet med dissemineret sklerose, dens detektion og kvantificering

Country Status (13)

Country Link
US (2) US5876954A (da)
EP (1) EP0667354B1 (da)
JP (1) JP2803910B2 (da)
AT (1) ATE205856T1 (da)
AU (1) AU701972B2 (da)
CA (1) CA2142557C (da)
DE (1) DE69522725T2 (da)
DK (1) DK0667354T3 (da)
FI (1) FI954876A (da)
FR (1) FR2716198B1 (da)
NO (1) NO954081L (da)
NZ (1) NZ281260A (da)
WO (1) WO1995021859A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3611856B2 (ja) 1994-02-04 2005-01-19 ベーイーオー・メリュー 多発性硬化症に関与するｍｓｒｖ１ウイルスおよびｍｓｒｖ２病因性及び／又は感染性の作因、核酸成分およびその応用
US6284236B1 (en) 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
FR2745974B1 (fr) * 1996-03-14 1998-04-17 Animal modifie, utilisations et procede pour mesurer l'efficacite d'un procede therapeutique
DK0925504T3 (da) * 1996-09-12 2001-07-23 Bio Merieux Fremgangsmåde til påvisning og/eller kvantitativ bestemmelse af en gliotoksisk faktor
WO1998023755A1 (en) * 1996-11-26 1998-06-04 Bio Merieux Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes
FR2765588A1 (fr) 1997-07-07 1999-01-08 Bio Merieux Materiel nucleique retroviral et fragments nucleotidiques notamment associes a la sclerose en plaques et/ou la polyarthrite rhumatoide, a des fins de diagnostic, prophylactiques et therapeutiques
FR2797402B1 (fr) 1999-07-15 2004-03-12 Biomerieux Stelhys Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2964721D1 (en) * 1978-08-24 1983-03-17 Nat Res Dev Pasteurellosis vaccines
US4311686A (en) * 1979-04-30 1982-01-19 The Immunology Development Corporation Methodology for the immunodiagnosis of multiple sclerosis and/or malignant diseases from blood sample analysis
US4396600A (en) * 1980-12-18 1983-08-02 Gus Gallucci Adult schistosome worm-derived antigenic substance and method of obtaining same
US4388298A (en) * 1982-07-14 1983-06-14 The United States Of America As Represented By The Secretary Of Agriculture Propagation of hemorrhagic enteritis virus in a turkey cell line and vaccine produced
GB8324800D0 (en) * 1983-09-15 1983-10-19 Pasteur Institut Antigens
US4647773A (en) * 1984-04-23 1987-03-03 The United States Of America As Represented By The Department Of Health And Human Services Method of continuous production of retroviruses (HTLV-III) from patients with AIDS and pre-AIDS
US4520113A (en) * 1984-04-23 1985-05-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions
NZ218050A (en) * 1985-11-13 1989-05-29 Wistar Inst Test for the presence of htlv-1v
US4900553A (en) * 1987-09-11 1990-02-13 Case Western Reserve University Method of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use of activated immature astrocytes
EP0326395A2 (en) * 1988-01-29 1989-08-02 City Of Hope Method of detecting and identifying certain viral sequences
FR2651581B1 (fr) * 1989-09-06 1994-05-13 Centre Nal Recherc Scientifique Moyens pour le diagnostic de neuropathies demyelinisantes, en particulier de la sclerose en plaques.
US5219837A (en) * 1990-06-21 1993-06-15 Trustees Of The University Of Pennsylvania Method of stimulating myelination of cells
US5158976A (en) * 1990-10-29 1992-10-27 The Children's Medical Center Corporation Controlling glutamine/glutamate related neuronal injury
DK173091D0 (da) * 1991-10-11 1991-10-11 Schleroseforeningen The Danish Biologisk materiale
FR2689520B1 (fr) * 1992-04-03 1996-07-19 Bio Merieux Procede et milieu de culture pour l'obtention de cellules infectees par un virus associe a la sclerose en plaques.
FR2689521B1 (fr) * 1992-04-03 1996-07-19 Bio Merieux Procede d'obtention et maintien d'une culture cellulaire viable, infectee par un virus associe a la sclerose en plaques, et produits biologiques derives de ladite culture.
ATE314479T1 (de) * 1992-05-18 2006-01-15 Genentech Inc Aktivierung von rezeptoren fähig zur oligomerisierung durch verwendung von fusionierten rezeptor liganden
GB9310657D0 (en) * 1993-05-24 1993-07-07 Univ London Retrovirus

Also Published As

Publication number Publication date
JPH08511808A (ja) 1996-12-10
AU1815295A (en) 1995-08-29
NO954081D0 (no) 1995-10-13
EP0667354A1 (fr) 1995-08-16
AU701972B2 (en) 1999-02-11
FR2716198B1 (fr) 1996-04-19
WO1995021859A1 (fr) 1995-08-17
DE69522725D1 (de) 2001-10-25
US5876954A (en) 1999-03-02
CA2142557C (fr) 2001-11-20
FI954876A0 (fi) 1995-10-13
DE69522725T2 (de) 2002-07-04
CA2142557A1 (fr) 1995-08-16
ATE205856T1 (de) 2001-10-15
JP2803910B2 (ja) 1998-09-24
NZ281260A (en) 1998-05-27
FI954876A (fi) 1995-10-13
EP0667354B1 (fr) 2001-09-19
NO954081L (no) 1995-12-13
US5728540A (en) 1998-03-17
FR2716198A1 (fr) 1995-08-18

Similar Documents

Publication Publication Date Title
ITMI940326A0 (it) Derivati del 3,8-diazabiciclo[3.2.1.]lottano ad attivita' analgesica
ATA188592A (de) Alkyl-bisacylphosphinoxide, diese enthaltende zusammensetzungen und ihre verwendung
DE69113810D1 (de) (poly)sulfid enthaltende polycitraconimide und polyitaconimide.
DE59100682D1 (de) Atemschutzmaske.
DE69212620D1 (de) Verwendung von Glycosaminoglycanen zur Behandlung von diabetischer Nephropathie und diabetischer Neuropathie
FR2676618B1 (fr) Dispositif pour la protection des cultures des predateurs diurnes et nocturnes.
DE69228492D1 (de) 3,4,N-Trisubstituierte-4,5-dihydro-1H-Pyrazol-1-carboxamide und deren Anwendung als Insektizide
DE69214718D1 (de) 4,4'-Biphenylendiphosphonit Verbindungen und ihre Verwendung
DE59201902D1 (de) Verstellbarer Rollstuhl.
DK0667354T3 (da) Cytotoksisk faktor forbundet med dissemineret sklerose, dens detektion og kvantificering
NO911429L (no) Stoffbehandling.
DE69213362D1 (de) Elektrolyseur und Herstellung davon
NO911430D0 (no) Stoffbehandlingsmetode.
NO932502L (no) Nye fosfolipidderivater
DE69016196D1 (de) Propanolderivate und diese enthaltende Duftstoffe.
IT1252659B (it) Procedimento per la depurazione dell'1,1,1-trifluoro-2-fluoroetano e dell'1,1,1-trifluoro-2,2-dicloroetano
FR2682457B1 (fr) Feu d'avertissement tournant, du type gyrophare.
ES2039312T1 (es) Peptido bacteriocinico.
FR2671794B1 (fr) Verre d'ophtalmologie tres resistant aux acides.
NO905316D0 (no) Transportabel roekvarsler.
DK61092A (da) Trachealkanyle
FR2696643B1 (fr) Dispersat purifiant désinfectant odorisant.
ATE126981T1 (de) Aufhängungshalterung und diese enthaltende aufhängungsanordnung.
DE69111209D1 (de) Herstellung und Reinigung von 3,4-Dihydrocumarin.
KR930020525U (ko) 살균탈취 장치가 부설된 전화기